img

Global and United States Oral Vaccine for Human Market Report & Forecast 2024-2034


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global and United States Oral Vaccine for Human Market Report & Forecast 2024-2034

Orally administered vaccines are of interest, as they elicit both systemic and mucosal immunities, in which mucosal immunity would neutralize the mucosa invading pathogen before the onset of an infection. 
Market Analysis and InsightsGlobal and United States Oral Vaccine for Human Market
This report focuses on global and United States Oral Vaccine for Human market, also covers the segmentation data of other regions in regional level and county level.
The global Oral Vaccine for Human revenue was US$ 2540 million in 2024 and is forecast to a readjusted size of US$ 3746.5 million by 2034 with a CAGR of 5.7% during the forecast period (2024-2034).
In United States the Oral Vaccine for Human revenue is expected to grow from US$ million in 2024 to US$ million by 2034, at a CAGR of % during the forecast period (2024-2034).
The global key players of Oral Vaccine for Human include Merck, GSK, Sanofi, Lanzhou Institute, Serum Institute, Valneva, Shanghai United Cell, Bibcol and PaxVax, etc. The global five biggest players hold a share of % in 2024.
Global Oral Vaccine for Human Scope and Market Size
Oral Vaccine for Human market is segmented in regional and country, by players, by type and by application. Companies, stakeholders, and other participants in the global Oral Vaccine for Human market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by type and by application for the period 2018-2034.
For United States market, this report focuses on the Oral Vaccine for Human market size by players, by Type and by Application, for the period 2018-2034. The key players include the global and local players, which play important roles in United States.



By Company


Merck
GSK
Sanofi
Lanzhou Institute
Serum Institute
Valneva
Shanghai United Cell
Bibcol
PaxVax
Vabiotech
Tiantan Biological
EuBiologics
Panacea Biotec Ltd
Bio-Med
Halfkin Bio-Pharmaceuticals
Segment by Type
Rotavirus Vaccine
Cholera Vaccine
Oral Polio Vaccine
Other

Segment by Application


Public
Private
By Region
Americas
United States
Canada
Mexico
Brazil
China
APAC (excluding China)
Japan
South Korea
China Taiwan
ASEAN
India
EMEA
Europe
Middle East
Africa

Chapter Introduction


Chapter 1Introduces Oral Vaccine for Human definition, global sales (volume and revenue), United States market size, United States percentage in global market. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 2Provides the analysis of various market segments by type, covering the volume, price, revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3Provides the analysis of various market segments by application, covering the revenue, price, volume, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4Detailed analysis of Oral Vaccine for Human companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Revenue and volume of Oral Vaccine for Human in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 6Americas by type, by application and by country, sales, and revenue for each segment.
Chapter 7EMEA by type, by application and by region, sales, and revenue for each segment.
Chapter 8China by type, by application, sales, and revenue for each segment.
Chapter 9APAC (excluding China) by type, by application and by region, sales, and revenue for each segment.
Chapter 10Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Oral Vaccine for Human sales, revenue, gross margin, and recent development, etc.
Chapter 11Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 12Research findings and conclusion

Table of Content

1 Study Coverage
1.1 Oral Vaccine for Human Product Introduction
1.2 Global Oral Vaccine for Human Outlook 2018 VS 2024 VS 2034
1.2.1 Global Oral Vaccine for Human Sales in US$ Million for the Year 2018-2034
1.2.2 Global Oral Vaccine for Human Sales in Volume for the Year 2018-2034
1.3 United States Oral Vaccine for Human Outlook 2018 VS 2024 VS 2034
1.3.1 United States Oral Vaccine for Human Sales in US$ Million for the Year 2018-2034
1.3.2 United States Oral Vaccine for Human Sales in Volume for the Year 2018-2034
1.4 Oral Vaccine for Human Market Size, United States VS Global, 2018 VS 2024 VS 2034
1.4.1 The Market Share of United States Oral Vaccine for Human in Global, 2018 VS 2024 VS 2034
1.4.2 The Growth Rate of Oral Vaccine for Human Market Size, United States VS Global, 2018 VS 2024 VS 2034
1.5 Oral Vaccine for Human Market Dynamics
1.5.1 Oral Vaccine for Human Industry Trends
1.5.2 Oral Vaccine for Human Market Drivers
1.5.3 Oral Vaccine for Human Market Challenges
1.5.4 Oral Vaccine for Human Market Restraints
1.6 Study Objectives
1.7 Years Considered
1.8 Years Considered
2 Oral Vaccine for Human by Type
2.1 Oral Vaccine for Human Market Segment by Type
2.1.1 Rotavirus Vaccine
2.1.2 Cholera Vaccine
2.1.3 Oral Polio Vaccine
2.1.4 Other
2.2 Global Oral Vaccine for Human Market Size by Type
2.2.1 Global Oral Vaccine for Human Sales in Value, by Type (2018, 2024 & 2034)
2.2.2 Global Oral Vaccine for Human Sales in Volume, by Type (2018, 2024 & 2034)
2.2.3 Global Oral Vaccine for Human Average Selling Price (ASP) by Type (2018, 2024 & 2034)
2.3 United States Oral Vaccine for Human Market Size by Type
2.3.1 United States Oral Vaccine for Human Sales in Value, by Type (2018, 2024 & 2034)
2.3.2 United States Oral Vaccine for Human Sales in Volume, by Type (2018, 2024 & 2034)
2.3.3 United States Oral Vaccine for Human Average Selling Price (ASP) by Type (2018, 2024 & 2034)
3 Oral Vaccine for Human by Application
3.1 Oral Vaccine for Human Market Segment by Application
3.1.1 Public
3.1.2 Private
3.2 Global Oral Vaccine for Human Market Size by Application
3.2.1 Global Oral Vaccine for Human Sales in Value, by Application (2018, 2024 & 2034)
3.2.2 Global Oral Vaccine for Human Sales in Volume, by Application (2018, 2024 & 2034)
3.3.3 Global Oral Vaccine for Human Average Selling Price (ASP) by Application (2018, 2024 & 2034)
3.3 United States Oral Vaccine for Human Market Size by Application
3.3.1 United States Oral Vaccine for Human Sales in Value, by Application (2018, 2024 & 2034)
3.3.2 United States Oral Vaccine for Human Sales in Volume, by Application (2018, 2024 & 2034)
3.3.3 United States Oral Vaccine for Human Average Selling Price (ASP) by Application (2018, 2024 & 2034)
4 Global Oral Vaccine for Human Competitor Landscape by Company
4.1 Global Oral Vaccine for Human Market Size by Company
4.1.1 Global Key Manufacturers of Oral Vaccine for Human, Ranked by Revenue (2024)
4.1.2 Global Oral Vaccine for Human Revenue by Manufacturer (2018-2023)
4.1.3 Global Oral Vaccine for Human Sales by Manufacturer (2018-2023)
4.1.4 Global Oral Vaccine for Human Price by Manufacturer (2018-2023)
4.2 Global Oral Vaccine for Human Concentration Ratio (CR)
4.2.1 Oral Vaccine for Human Market Concentration Ratio (CR)
4.2.2 Global Top 5 and Top 10 Largest Manufacturers of Oral Vaccine for Human in 2024
4.2.3 Global Oral Vaccine for Human Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.3 Global Key Manufacturers of Oral Vaccine for Human, Manufacturing Base Distribution and Headquarters
4.4 Global Key Manufacturers of Oral Vaccine for Human, Product Offered and Application
4.5 Global Key Manufacturers of Oral Vaccine for Human, Date of Enter into This Industry
4.6 Manufacturers Mergers & Acquisitions, Expansion Plans
4.7 United States Oral Vaccine for Human Market Size by Company
4.7.1 Key Players of Oral Vaccine for Human in United States, Ranked by Revenue (2024)
4.7.2 United States Oral Vaccine for Human Revenue by Players (2018-2023)
4.7.3 United States Oral Vaccine for Human Sales by Players (2018-2023)
5 Global Oral Vaccine for Human Market Size by Region
5.1 Global Oral Vaccine for Human Market Size by Region: 2018 VS 2024 VS 2034
5.2 Global Oral Vaccine for Human Market Size in Volume by Region (2018-2034)
5.2.1 Global Oral Vaccine for Human Sales in Volume by Region: 2018-2023
5.2.2 Global Oral Vaccine for Human Sales in Volume Forecast by Region (2024-2034)
5.3 Global Oral Vaccine for Human Market Size in Value by Region (2018-2034)
5.3.1 Global Oral Vaccine for Human Sales in Value by Region: 2018-2023
5.3.2 Global Oral Vaccine for Human Sales in Value by Region: 2024-2034
6 Americas
6.1 Americas Oral Vaccine for Human Market Size YoY Growth 2018-2034
6.2 Americas Oral Vaccine for Human Sales in Volume, by Type (2018, 2024 & 2034)
6.3 Americas Oral Vaccine for Human Sales in Volume, by Application (2018, 2024 & 2034)
6.4 Americas Oral Vaccine for Human Market Facts & Figures by Country (2018, 2024 & 2034)
6.4.1 Americas Oral Vaccine for Human Sales in Value by Country (2018, 2024 & 2034)
6.4.2 Americas Oral Vaccine for Human Sales in Volume by Country (2018, 2024 & 2034)
6.4.3 United States
6.4.4 Canada
6.4.5 Mexico
6.4.6 Brazil
7 EMEA
7.1 EMEA Oral Vaccine for Human Market Size YoY Growth 2018-2034
7.2 EMEA Oral Vaccine for Human Sales in Volume, by Type (2018, 2024 & 2034)
7.3 EMEA Oral Vaccine for Human Sales in Volume, by Application (2018, 2024 & 2034)
7.4 EMEA Oral Vaccine for Human Market Facts & Figures by Country (2018, 2024 & 2034)
7.4.1 EMEA Oral Vaccine for Human Sales in Value by Country (2018, 2024 & 2034)
7.4.2 EMEA Oral Vaccine for Human Sales in Volume by Country (2018, 2024 & 2034)
7.4.3 Europe
7.4.4 Middle East
7.4.5 Africa
8 China
8.1 China Oral Vaccine for Human Market Size YoY Growth 2018-2034
8.2 China Oral Vaccine for Human Sales in Volume, by Type (2018, 2024 & 2034)
8.3 China Oral Vaccine for Human Sales in Volume, by Application (2018, 2024 & 2034)
9 APAC
9.1 APAC Oral Vaccine for Human Market Size YoY Growth 2018-2034
9.2 APAC Oral Vaccine for Human Sales in Volume, by Type (2018, 2024 & 2034)
9.3 APAC Oral Vaccine for Human Sales in Volume, by Application (2018, 2024 & 2034)
9.4 APAC Oral Vaccine for Human Market Facts & Figures by Region (2018, 2024 & 2034)
9.4.1 APAC Oral Vaccine for Human Sales in Value by Region (2018, 2024 & 2034)
9.4.2 APAC Oral Vaccine for Human Sales in Volume by Region (2018, 2024 & 2034)
9.4.3 Japan
9.4.4 South Korea
9.4.5 China Taiwan
9.4.6 Southeast Asia
9.4.7 India
10 Company Profiles
10.1 Merck
10.1.1 Merck Company Information
10.1.2 Merck Description and Business Overview
10.1.3 Merck Oral Vaccine for Human Sales, Revenue and Gross Margin (2018-2023)
10.1.4 Merck Oral Vaccine for Human Products Offered
10.1.5 Merck Recent Development
10.2 GSK
10.2.1 GSK Company Information
10.2.2 GSK Description and Business Overview
10.2.3 GSK Oral Vaccine for Human Sales, Revenue and Gross Margin (2018-2023)
10.2.4 GSK Oral Vaccine for Human Products Offered
10.2.5 GSK Recent Development
10.3 Sanofi
10.3.1 Sanofi Company Information
10.3.2 Sanofi Description and Business Overview
10.3.3 Sanofi Oral Vaccine for Human Sales, Revenue and Gross Margin (2018-2023)
10.3.4 Sanofi Oral Vaccine for Human Products Offered
10.3.5 Sanofi Recent Development
10.4 Lanzhou Institute
10.4.1 Lanzhou Institute Company Information
10.4.2 Lanzhou Institute Description and Business Overview
10.4.3 Lanzhou Institute Oral Vaccine for Human Sales, Revenue and Gross Margin (2018-2023)
10.4.4 Lanzhou Institute Oral Vaccine for Human Products Offered
10.4.5 Lanzhou Institute Recent Development
10.5 Serum Institute
10.5.1 Serum Institute Company Information
10.5.2 Serum Institute Description and Business Overview
10.5.3 Serum Institute Oral Vaccine for Human Sales, Revenue and Gross Margin (2018-2023)
10.5.4 Serum Institute Oral Vaccine for Human Products Offered
10.5.5 Serum Institute Recent Development
10.6 Valneva
10.6.1 Valneva Company Information
10.6.2 Valneva Description and Business Overview
10.6.3 Valneva Oral Vaccine for Human Sales, Revenue and Gross Margin (2018-2023)
10.6.4 Valneva Oral Vaccine for Human Products Offered
10.6.5 Valneva Recent Development
10.7 Shanghai United Cell
10.7.1 Shanghai United Cell Company Information
10.7.2 Shanghai United Cell Description and Business Overview
10.7.3 Shanghai United Cell Oral Vaccine for Human Sales, Revenue and Gross Margin (2018-2023)
10.7.4 Shanghai United Cell Oral Vaccine for Human Products Offered
10.7.5 Shanghai United Cell Recent Development
10.8 Bibcol
10.8.1 Bibcol Company Information
10.8.2 Bibcol Description and Business Overview
10.8.3 Bibcol Oral Vaccine for Human Sales, Revenue and Gross Margin (2018-2023)
10.8.4 Bibcol Oral Vaccine for Human Products Offered
10.8.5 Bibcol Recent Development
10.9 PaxVax
10.9.1 PaxVax Company Information
10.9.2 PaxVax Description and Business Overview
10.9.3 PaxVax Oral Vaccine for Human Sales, Revenue and Gross Margin (2018-2023)
10.9.4 PaxVax Oral Vaccine for Human Products Offered
10.9.5 PaxVax Recent Development
10.10 Vabiotech
10.10.1 Vabiotech Company Information
10.10.2 Vabiotech Description and Business Overview
10.10.3 Vabiotech Oral Vaccine for Human Sales, Revenue and Gross Margin (2018-2023)
10.10.4 Vabiotech Oral Vaccine for Human Products Offered
10.10.5 Vabiotech Recent Development
10.11 Tiantan Biological
10.11.1 Tiantan Biological Company Information
10.11.2 Tiantan Biological Description and Business Overview
10.11.3 Tiantan Biological Oral Vaccine for Human Sales, Revenue and Gross Margin (2018-2023)
10.11.4 Tiantan Biological Oral Vaccine for Human Products Offered
10.11.5 Tiantan Biological Recent Development
10.12 EuBiologics
10.12.1 EuBiologics Company Information
10.12.2 EuBiologics Description and Business Overview
10.12.3 EuBiologics Oral Vaccine for Human Sales, Revenue and Gross Margin (2018-2023)
10.12.4 EuBiologics Oral Vaccine for Human Products Offered
10.12.5 EuBiologics Recent Development
10.13 Panacea Biotec Ltd
10.13.1 Panacea Biotec Ltd Company Information
10.13.2 Panacea Biotec Ltd Description and Business Overview
10.13.3 Panacea Biotec Ltd Oral Vaccine for Human Sales, Revenue and Gross Margin (2018-2023)
10.13.4 Panacea Biotec Ltd Oral Vaccine for Human Products Offered
10.13.5 Panacea Biotec Ltd Recent Development
10.14 Bio-Med
10.14.1 Bio-Med Company Information
10.14.2 Bio-Med Description and Business Overview
10.14.3 Bio-Med Oral Vaccine for Human Sales, Revenue and Gross Margin (2018-2023)
10.14.4 Bio-Med Oral Vaccine for Human Products Offered
10.14.5 Bio-Med Recent Development
10.15 Halfkin Bio-Pharmaceuticals
10.15.1 Halfkin Bio-Pharmaceuticals Company Information
10.15.2 Halfkin Bio-Pharmaceuticals Description and Business Overview
10.15.3 Halfkin Bio-Pharmaceuticals Oral Vaccine for Human Sales, Revenue and Gross Margin (2018-2023)
10.15.4 Halfkin Bio-Pharmaceuticals Oral Vaccine for Human Products Offered
10.15.5 Halfkin Bio-Pharmaceuticals Recent Development
11 Industry Chain and Sales Channels Analysis
11.1 Oral Vaccine for Human Industry Chain Analysis
11.2 Oral Vaccine for Human Key Raw Materials
11.2.1 Key Raw Materials
11.2.2 Raw Materials Key Suppliers
11.3 Oral Vaccine for Human Production Mode & Process
11.4 Oral Vaccine for Human Sales and Marketing
11.4.1 Oral Vaccine for Human Sales Channels
11.4.2 Oral Vaccine for Human Distributors
11.5 Oral Vaccine for Human Customers
12 Research Findings and Conclusion
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer

List of Figure

List of Tables
Table 1. Oral Vaccine for Human CAGR in Value, United States VS Global, 2018 VS 2024 VS 2034
Table 2. Oral Vaccine for Human Market Trends
Table 3. Oral Vaccine for Human Market Drivers
Table 4. Oral Vaccine for Human Market Challenges
Table 5. Oral Vaccine for Human Market Restraints
Table 6. Global Oral Vaccine for Human Sales Growth Rate (CAGR) by Type: 2018 VS 2024 VS 2034 (US$ Million)
Table 7. United States Oral Vaccine for Human Sales Growth Rate (CAGR) by Type: 2018 VS 2024 VS 2034 (US$ Million)
Table 8. Global Oral Vaccine for Human Sales Growth Rate (CAGR) by Application: 2018 VS 2024 VS 2034 (US$ Million)
Table 9. United States Oral Vaccine for Human Sales Growth Rate (CAGR) by Application: 2018 VS 2024 VS 2034 (US$ Million)
Table 10. Global Key Manufacturers of Oral Vaccine for Human, Ranked by Revenue (2024) & (US$ Million)
Table 11. Global Oral Vaccine for Human Revenue by Manufacturer, (US$ Million), 2018-2023
Table 12. Global Oral Vaccine for Human Revenue Share by Manufacturer, 2018-2023
Table 13. Global Oral Vaccine for Human Sales by Manufacturer, (K Units), 2018-2023
Table 14. Global Oral Vaccine for Human Sales Share by Manufacturer, 2018-2023
Table 15. Global Oral Vaccine for Human Price by Manufacturer (2018-2023) & (US$/Unit)
Table 16. Global Oral Vaccine for Human Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 17. Global Oral Vaccine for Human by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oral Vaccine for Human as of 2024)
Table 18. Global Key Manufacturers of Oral Vaccine for Human, Manufacturing Base Distribution and Headquarters
Table 19. Global Key Manufacturers of Oral Vaccine for Human, Product Offered and Application
Table 20. Global Key Manufacturers of Oral Vaccine for Human, Date of Enter into This Industry
Table 21. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 22. Key Players of Oral Vaccine for Human in United States, Ranked by Revenue (2024) & (US$ million)
Table 23. United States Oral Vaccine for Human Revenue by Players, (US$ Million), (2018-2023)
Table 24. United States Oral Vaccine for Human Revenue Share by Players, (2018-2023)
Table 25. United States Oral Vaccine for Human Sales by Players, (K Units), (2018-2023)
Table 26. United States Oral Vaccine for Human Sales Share by Players, (2018-2023)
Table 27. Global Oral Vaccine for Human Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2024 VS 2034
Table 28. Global Oral Vaccine for Human Sales in Volume by Region (2018-2023) & (K Units)
Table 29. Global Oral Vaccine for Human Sales in Volume Forecast by Region (2024-2034) & (K Units)
Table 30. Global Oral Vaccine for Human Sales in Value by Region (2018-2023) & (US$ Million)
Table 31. Global Oral Vaccine for Human Sales in Value Forecast by Region (2024-2034) & (US$ Million)
Table 32. Americas Oral Vaccine for Human Market Size Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2024 VS 2034
Table 33. Americas Oral Vaccine for Human Sales in Value by Country (2018-2023) & (US$ Million)
Table 34. Americas Oral Vaccine for Human Sales in Value by Country (2024-2034) & (US$ Million)
Table 35. Americas Oral Vaccine for Human Sales in Volume by Country (2018-2023) & (K Units)
Table 36. Americas Oral Vaccine for Human Sales in Volume by Country (2024-2034) & (K Units)
Table 37. EMEA Oral Vaccine for Human Market Size Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2024 VS 2034
Table 38. EMEA Oral Vaccine for Human Sales in Value by Country (2018-2023) & (US$ Million)
Table 39. EMEA Oral Vaccine for Human Sales in Value by Country (2024-2034) & (US$ Million)
Table 40. EMEA Oral Vaccine for Human Sales in Volume by Country (2018-2023) & (K Units)
Table 41. EMEA Oral Vaccine for Human Sales in Volume by Country (2024-2034) & (K Units)
Table 42. APAC Oral Vaccine for Human Market Size Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2024 VS 2034
Table 43. APAC Oral Vaccine for Human Sales in Value by Country (2018-2023) & (US$ Million)
Table 44. APAC Oral Vaccine for Human Sales in Value by Country (2024-2034) & (US$ Million)
Table 45. APAC Oral Vaccine for Human Sales in Volume by Country (2018-2023) & (K Units)
Table 46. APAC Oral Vaccine for Human Sales in Volume by Country (2024-2034) & (K Units)
Table 47. Merck Company Information
Table 48. Merck Description and Business Overview
Table 49. Merck Oral Vaccine for Human Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 50. Merck Oral Vaccine for Human Product
Table 51. Merck Recent Development
Table 52. GSK Company Information
Table 53. GSK Description and Business Overview
Table 54. GSK Oral Vaccine for Human Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 55. GSK Oral Vaccine for Human Product
Table 56. GSK Recent Development
Table 57. Sanofi Company Information
Table 58. Sanofi Description and Business Overview
Table 59. Sanofi Oral Vaccine for Human Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 60. Sanofi Oral Vaccine for Human Product
Table 61. Sanofi Recent Development
Table 62. Lanzhou Institute Company Information
Table 63. Lanzhou Institute Description and Business Overview
Table 64. Lanzhou Institute Oral Vaccine for Human Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 65. Lanzhou Institute Oral Vaccine for Human Product
Table 66. Lanzhou Institute Recent Development
Table 67. Serum Institute Company Information
Table 68. Serum Institute Description and Business Overview
Table 69. Serum Institute Oral Vaccine for Human Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 70. Serum Institute Oral Vaccine for Human Product
Table 71. Serum Institute Recent Development
Table 72. Valneva Company Information
Table 73. Valneva Description and Business Overview
Table 74. Valneva Oral Vaccine for Human Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 75. Valneva Oral Vaccine for Human Product
Table 76. Valneva Recent Development
Table 77. Shanghai United Cell Company Information
Table 78. Shanghai United Cell Description and Business Overview
Table 79. Shanghai United Cell Oral Vaccine for Human Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 80. Shanghai United Cell Oral Vaccine for Human Product
Table 81. Shanghai United Cell Recent Development
Table 82. Bibcol Company Information
Table 83. Bibcol Description and Business Overview
Table 84. Bibcol Oral Vaccine for Human Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 85. Bibcol Oral Vaccine for Human Product
Table 86. Bibcol Recent Development
Table 87. PaxVax Company Information
Table 88. PaxVax Description and Business Overview
Table 89. PaxVax Oral Vaccine for Human Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 90. PaxVax Oral Vaccine for Human Product
Table 91. PaxVax Recent Development
Table 92. Vabiotech Company Information
Table 93. Vabiotech Description and Business Overview
Table 94. Vabiotech Oral Vaccine for Human Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 95. Vabiotech Oral Vaccine for Human Product
Table 96. Vabiotech Recent Development
Table 97. Tiantan Biological Company Information
Table 98. Tiantan Biological Description and Business Overview
Table 99. Tiantan Biological Oral Vaccine for Human Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 100. Tiantan Biological Oral Vaccine for Human Product
Table 101. Tiantan Biological Recent Development
Table 102. EuBiologics Company Information
Table 103. EuBiologics Description and Business Overview
Table 104. EuBiologics Oral Vaccine for Human Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 105. EuBiologics Oral Vaccine for Human Product
Table 106. EuBiologics Recent Development
Table 107. Panacea Biotec Ltd Company Information
Table 108. Panacea Biotec Ltd Description and Business Overview
Table 109. Panacea Biotec Ltd Oral Vaccine for Human Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 110. Panacea Biotec Ltd Oral Vaccine for Human Product
Table 111. Panacea Biotec Ltd Recent Development
Table 112. Bio-Med Company Information
Table 113. Bio-Med Description and Business Overview
Table 114. Bio-Med Oral Vaccine for Human Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 115. Bio-Med Oral Vaccine for Human Product
Table 116. Bio-Med Recent Development
Table 117. Halfkin Bio-Pharmaceuticals Company Information
Table 118. Halfkin Bio-Pharmaceuticals Description and Business Overview
Table 119. Halfkin Bio-Pharmaceuticals Oral Vaccine for Human Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 120. Halfkin Bio-Pharmaceuticals Oral Vaccine for Human Product
Table 121. Halfkin Bio-Pharmaceuticals Recent Development
Table 122. Key Raw Materials Lists
Table 123. Raw Materials Key Suppliers Lists
Table 124. Oral Vaccine for Human Customers List
Table 125. Oral Vaccine for Human Distributors List
Table 126. Research Programs/Design for This Report
Table 127. Key Data Information from Secondary Sources
Table 128. Key Data Information from Primary Sources
List of Figures
Figure 1. Oral Vaccine for Human Product Picture
Figure 2. Global Oral Vaccine for Human Revenue, (US$ Million), 2018 VS 2024 VS 2034
Figure 3. Global Oral Vaccine for Human Market Size 2018-2034 (US$ Million)
Figure 4. Global Oral Vaccine for Human Sales 2018-2034 (K Units)
Figure 5. United States Oral Vaccine for Human Revenue, (US$ Million), 2018 VS 2024 VS 2034
Figure 6. United States Oral Vaccine for Human Market Size 2018-2034 (US$ Million)
Figure 7. United States Oral Vaccine for Human Sales 2018-2034 (K Units)
Figure 8. United States Oral Vaccine for Human Market Share in Global, in Value (US$ Million) 2018-2034
Figure 9. United States Oral Vaccine for Human Market Share in Global, in Volume (K Units) 2018-2034
Figure 10. Oral Vaccine for Human Report Years Considered
Figure 11. Product Picture of Rotavirus Vaccine
Figure 12. Product Picture of Cholera Vaccine
Figure 13. Product Picture of Oral Polio Vaccine
Figure 14. Product Picture of Other
Figure 15. Global Oral Vaccine for Human Market Share by Type in 2024 & 2034
Figure 16. Global Oral Vaccine for Human Sales in Value by Type (2018-2034) & (US$ Million)
Figure 17. Global Oral Vaccine for Human Sales Market Share in Value by Type (2018-2034)
Figure 18. Global Oral Vaccine for Human Sales by Type (2018-2034) & (K Units)
Figure 19. Global Oral Vaccine for Human Sales Market Share in Volume by Type (2018-2034)
Figure 20. Global Oral Vaccine for Human Price by Type (2018-2034) & (US$/Unit)
Figure 21. United States Oral Vaccine for Human Market Share by Type in 2024 & 2034
Figure 22. United States Oral Vaccine for Human Sales in Value by Type (2018-2034) & (US$ Million)
Figure 23. United States Oral Vaccine for Human Sales Market Share in Value by Type (2018-2034)
Figure 24. United States Oral Vaccine for Human Sales by Type (2018-2034) & (K Units)
Figure 25. United States Oral Vaccine for Human Sales Market Share in Volume by Type (2018-2034)
Figure 26. United States Oral Vaccine for Human Price by Type (2018-2034) & (US$/Unit)
Figure 27. Product Picture of Public
Figure 28. Product Picture of Private
Figure 29. Global Oral Vaccine for Human Market Share by Application in 2024 & 2034
Figure 30. Global Oral Vaccine for Human Sales in Value by Application (2018-2034) & (US$ Million)
Figure 31. Global Oral Vaccine for Human Sales Market Share in Value by Application (2018-2034)
Figure 32. Global Oral Vaccine for Human Sales by Application (2018-2034) & (K Units)
Figure 33. Global Oral Vaccine for Human Sales Market Share in Volume by Application (2018-2034)
Figure 34. Global Oral Vaccine for Human Price by Application (2018-2034) & (US$/Unit)
Figure 35. United States Oral Vaccine for Human Market Share by Application in 2024 & 2034
Figure 36. United States Oral Vaccine for Human Sales in Value by Application (2018-2034) & (US$ Million)
Figure 37. United States Oral Vaccine for Human Sales Market Share in Value by Application (2018-2034)
Figure 38. United States Oral Vaccine for Human Sales by Application (2018-2034) & (K Units)
Figure 39. United States Oral Vaccine for Human Sales Market Share in Volume by Application (2018-2034)
Figure 40. United States Oral Vaccine for Human Price by Application (2018-2034) & (US$/Unit)
Figure 41. Americas Oral Vaccine for Human Sales in Volume Growth Rate 2018-2034 (K Units)
Figure 42. Americas Oral Vaccine for Human Sales in Value Growth Rate 2018-2034 (US$ Million)
Figure 43. Americas Oral Vaccine for Human Sales by Type (2018-2034) & (K Units)
Figure 44. Americas Oral Vaccine for Human Sales Market Share in Volume by Type (2018-2034)
Figure 45. Americas Oral Vaccine for Human Sales by Application (2018-2034) & (K Units)
Figure 46. Americas Oral Vaccine for Human Sales Market Share in Volume by Application (2018-2034)
Figure 47. United States Oral Vaccine for Human Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 48. Canada Oral Vaccine for Human Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 49. Mexico Oral Vaccine for Human Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 50. Brazil Oral Vaccine for Human Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 51. EMEA Oral Vaccine for Human Sales in Volume Growth Rate 2018-2034 (K Units)
Figure 52. EMEA Oral Vaccine for Human Sales in Value Growth Rate 2018-2034 (US$ Million)
Figure 53. EMEA Oral Vaccine for Human Sales by Type (2018-2034) & (K Units)
Figure 54. EMEA Oral Vaccine for Human Sales Market Share in Volume by Type (2018-2034)
Figure 55. EMEA Oral Vaccine for Human Sales by Application (2018-2034) & (K Units)
Figure 56. EMEA Oral Vaccine for Human Sales Market Share in Volume by Application (2018-2034)
Figure 57. Europe Oral Vaccine for Human Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 58. Middle East Oral Vaccine for Human Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 59. Africa Oral Vaccine for Human Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 60. China Oral Vaccine for Human Sales in Volume Growth Rate 2018-2034 (K Units)
Figure 61. China Oral Vaccine for Human Sales in Value Growth Rate 2018-2034 (US$ Million)
Figure 62. China Oral Vaccine for Human Sales by Type (2018-2034) & (K Units)
Figure 63. China Oral Vaccine for Human Sales Market Share in Volume by Type (2018-2034)
Figure 64. China Oral Vaccine for Human Sales by Application (2018-2034) & (K Units)
Figure 65. China Oral Vaccine for Human Sales Market Share in Volume by Application (2018-2034)
Figure 66. APAC Oral Vaccine for Human Sales in Volume Growth Rate 2018-2034 (K Units)
Figure 67. APAC Oral Vaccine for Human Sales in Value Growth Rate 2018-2034 (US$ Million)
Figure 68. APAC Oral Vaccine for Human Sales by Type (2018-2034) & (K Units)
Figure 69. APAC Oral Vaccine for Human Sales Market Share in Volume by Type (2018-2034)
Figure 70. APAC Oral Vaccine for Human Sales by Application (2018-2034) & (K Units)
Figure 71. APAC Oral Vaccine for Human Sales Market Share in Volume by Application (2018-2034)
Figure 72. Japan Oral Vaccine for Human Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 73. South Korea Oral Vaccine for Human Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 74. China Taiwan Oral Vaccine for Human Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 75. Southeast Asia Oral Vaccine for Human Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 76. India Oral Vaccine for Human Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 77. Oral Vaccine for Human Value Chain
Figure 78. Oral Vaccine for Human Production Process
Figure 79. Channels of Distribution
Figure 80. Distributors Profiles
Figure 81. Bottom-up and Top-down Approaches for This Report
Figure 82. Data Triangulation
Figure 83. Key Executives Interviewed